All Stories

  1. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649

    Article • Expert Opinion on Therapeutic Patents, October 2019, Taylor & Francis

    PhD Martin Perez-Santos, Lourdes Millán Pérez Peña

  2. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1

    Article • Expert Opinion on Therapeutic Patents, July 2019, Taylor & Francis

    PhD Martin Perez-Santos, Lourdes Millán Pérez Peña

  3. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1

    Article • Expert Opinion on Therapeutic Patents, June 2019, Taylor & Francis

    PhD Martin Perez-Santos, Lourdes Millán Pérez Peña